Garry Arthur Neil's Net Worth
-$472 Thousand
Who is Garry Arthur Neil?
Garry Arthur Neil does not have any significant net worth to report based on the numbers we have. This is based on reported shares across multiple companies, which include ARENA PHARMACEUTICALS INC, GTX INC /DE/, Avalo Therapeutics, Inc., Aevi Genomic Medicine, Inc., Celldex Therapeutics, Inc., and JATT Acquisition Corp.
SEC CIK
Garry Arthur Neil's CIK is 0001586785
Past Insider Trading and Trends
2017 was Garry Arthur Neil's most active year for acquiring shares with 13 total transactions. Garry Arthur Neil's most active month to acquire stocks was the month of May. 2020 was Garry Arthur Neil's most active year for disposing of shares, totalling 10 transactions. Garry Arthur Neil's most active month to dispose stocks was the month of January. 2019 saw Garry Arthur Neil paying a total of $287,116.38 for 2,071,564.884 shares, this is the most they've acquired in one year. In 2020 Garry Arthur Neil cashed out on 4,352,016 shares for a total of $0.00, their largest year based on trade value.
Attention insiders: Dive deeper into market movements and stay ahead of the curve with Benzinga Pro! From up-to-the-second news to audio squawks and interactive data tools, it's everything you need to supercharge your trading strategy. Experience the Benzinga Pro advantage today and transform the way you trade with our exclusive free trial!
ARENA PHARMACEUTICALS INC No price found
Investor
Form Type
|
Δ Own
|
Qty.
|
Price
|
Size ($)
|
Own
|
Filing Date
|
Type
|
Is Scheduled
|
Trade Dates
|
|---|---|---|---|---|---|---|---|---|---|
Form 4
| -100.00% | -11.22K |
—
|
—
|
0
|
Mar 11
| |||
Form 4
| +37.63% | 3.07K |
—
|
—
| 11.22K |
Jun 11
| |||
Form 4
| +42.88% | 2.45K |
—
|
—
| 8.15K |
Jun 12
| |||
Form 4
| +87.02% | 2.65K |
—
|
—
| 5.7K |
Jun 13
| |||
Form 4
|
∞
| 3.05K |
—
|
—
| 3.05K |
Jun 13
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Jun 13
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Feb 13
| |||
Form 3
|
—
|
0
|
—
|
—
|
0
| ||||
| No matching records found | |||||||||
GTX INC /DE/ (ONCT) Snapshot price: $4.47
Investor
Form Type
|
Δ Own
|
Qty.
|
Price
|
Size ($)
|
Own
|
Filing Date
|
Type
|
Is Scheduled
|
Trade Dates
|
|---|---|---|---|---|---|---|---|---|---|
Form 4
| +65.40% | 14.53K |
$0.86 | $12,500.00 | 36.76K |
Jan 2
| |||
Form 4
| +59.99% | 8.33K |
$1.50 | $12,500.00 | 22.22K |
Oct 1
| |||
Form 4
| +6.18% | 808.02 |
$15.47 | $12,500.01 | 13.89K |
Jul 2
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
May 10
| |||
Form 4
| +5.79% | 715.51 |
$17.47 | $12,499.99 | 13.08K |
Apr 2
| |||
Form 4
| +9.67% | 1.09K |
$11.46 | $12,500.00 | 12.37K |
Jan 2
| |||
Form 4
| +16.23% | 1.57K |
$7.94 | $12,500.00 | 11.28K |
Oct 2
| |||
Form 4
| +32.44% | 2.38K |
$5.26 | $12,500.00 | 9.7K |
Jul 3
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
May 12
| |||
Form 4
| +53.42% | 2.55K |
$4.90 | $12,500.00 | 7.33K |
Apr 3
| |||
Form 4
| +100.99% | 2.4K |
$5.21 | $12,500.00 | 4.77K |
Jan 3
| |||
Form 4
| +225.00% | 16.45K |
—
|
—
| 23.76K |
Oct 3
| |||
Form 4
|
∞
| 7.31K |
—
|
—
| 7.31K |
Sep 1
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Aug 31
| |||
Form 3
|
—
|
0
|
—
|
—
|
0
| ||||
| No matching records found | |||||||||
Avalo Therapeutics, Inc. (AVTX) Snapshot price: $7.25
CEO and Chairman the Board
Form Type
|
Δ Own
|
Qty.
|
Price
|
Size ($)
|
Own
|
Filing Date
|
Type
|
Is Scheduled
|
Trade Dates
|
|---|---|---|---|---|---|---|---|---|---|
Form 4
|
—
|
0
|
—
|
—
|
0
|
Aug 13
| |||
Form 4
| +43.38% | 4K |
$3.42 | $13,680.00 | 13.22K |
Jun 9
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
May 15
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Feb 13
| |||
Form 4
| +29.19% | 2.08K |
$4.42 | $9,206.86 | 9.22K |
Dec 9
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Oct 5
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Mar 8
| |||
Form 4
| +5.24% | 4.27K |
$1.57 | $6,699.19 | 85.64K |
Dec 10
| |||
Form 4
| +4.75% | 3.69K |
$2.28 | $8,417.76 | 81.37K |
Jun 10
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Jan 26
| |||
Form 4
| +4.86% | 3.6K |
$2.28 | $8,198.52 | 77.68K |
Dec 10
| |||
Form 4
| +2.49% | 1.8K |
$2.28 | $4,098.12 | 74.08K |
Jun 10
| |||
Form 4
|
∞
| 72.28K |
—
|
—
| 72.28K |
Feb 3
| |||
Form 3
|
—
|
0
|
—
|
—
|
0
| ||||
| No matching records found | |||||||||
Aevi Genomic Medicine, Inc. No price found
Chief Scientific Officer
Form Type
|
Δ Own
|
Qty.
|
Price
|
Size ($)
|
Own
|
Filing Date
|
Type
|
Is Scheduled
|
Trade Dates
|
|---|---|---|---|---|---|---|---|---|---|
Form 4
| -100.00% | -2.16M |
—
|
—
|
0
|
Feb 3
| |||
Form 4
| +1,785.58% | 2.05M |
$0.13 | $274,616.38 | 2.16M |
Dec 5
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Jun 14
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
May 14
| |||
Form 4/A
|
—
|
0
|
—
|
—
|
0
|
Aug 11
| |||
Form 4
| +188.57% | 75K |
$1.26 | $94,500.00 | 114.77K |
Oct 17
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Aug 11
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Feb 17
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Apr 15
| |||
Form 4
| +63.08% | 15.38K |
$6.50 | $99,996.00 | 39.77K |
Oct 6
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Feb 18
| |||
Form 4
|
∞
| 24.39K |
$4.10 | $99,999.00 | 24.39K |
Dec 1
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Apr 16
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Sep 13
| |||
Form 3
|
—
|
0
|
—
|
—
|
0
| ||||
| No matching records found | |||||||||
Celldex Therapeutics, Inc. (CLDX) Snapshot price: $44
Investor
Form Type
|
Δ Own
|
Qty.
|
Price
|
Size ($)
|
Own
|
Filing Date
|
Type
|
Is Scheduled
|
Trade Dates
|
|---|---|---|---|---|---|---|---|---|---|
Form 4
|
—
|
0
|
—
|
—
|
0
|
Jun 13
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Jun 15
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Jun 16
| |||
Form 3
|
—
|
0
|
—
|
—
|
0
| ||||
| No matching records found | |||||||||